skip to main content

Back to all Representative Matters
May 10, 2013

A&B Represents Cytochroma Canada Inc. in its Sale to Opko Health, Inc. for Gross Sale Proceeds of up to US$290 Million

On March 4, 2013, a subsidiary of OPKO Health, Inc. (NYSE:OPK), a multi-national biopharmaceutical and diagnostics company, completed the acquisition of all of the assets and undertaking of Cytochroma Canada Inc., a privately held pharmaceutical company with operations in Markham, Ontario and Bannockburn, Illinois. Cytochroma's lead products include CTAP101 Capsules, a vitamin D prohormone to treat secondary hyperparathyroidism (SHPT) in patients with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency, and Fermagate Tablets, a new and potent non-absorbed phosphate binder to treat hyperphosphatemia in CKD patients on chronic hemodialysis. The purchase price paid on closing was approximately US$100 Million and was satisfied by the issuance of OPKO common stock to Cytochroma. There is also an earn-out component for up to an additional US$190 Million, which is payable upon the satisfaction of certain regulatory and revenue milestones.

Cytochroma Canada Inc. was represented in Canada by Aird & Berlis LLP, with a team that included Richard Kimel, Tom Fenton, James Leech and Anne Markle (corporate finance), Barbara Worndl (tax), Aaron Collins (financial services) and Grant Cansfield (intellectual property); and in the United States by Cooley LLP, with a team that included Glen Sato (corporate/securities).

Related Representative Matters

Representative Matters
Allied Properties REIT Completes $345 Million Public Equity Offering Margaret T. Nelligan, Sherri M. Altshuler, Anne E. Miatello, Melanie Cole, Liam Tracey-Raymont, Amy Marcen-Gaudaur, Michael D. Smith, Neill Kalvin, Zale Skolnik and Barbara Worndl Jun 24, 2019 Allied Properties Real Estate Investment Trust, a leading owner, manager and developer of distinctive urban workspace in Canada’s major cities and network-dense urban data centres in Toronto that form Canada’s hub for global connectivity, recently completed a $345 million public equity offering o...
Representative Matters
MediPharm Labs Completes $75 Million Bought Deal Financing Melanie Cole, Amy Marcen-Gaudaur, Meredith McCann and Barbara Worndl Jun 18, 2019 MediPharm Labs Corp., a leader in specialized, research-driven cannabis extraction and cannabinoid isolation, recently completed a $75 million bought deal offering of common shares.
Representative Matters
Feronia Inc. Completes US$19.3 Million Private Placement and Debt Settlement Richard M. Kimel, Amy Marcen-Gaudaur and Clair Affleck-Jacques Jun 06, 2019 Feronia Inc. recently completed a US$19.3 million private placement of common shares issued to existing shareholders Straight KKM 2 Limited, CDC Group plc and Golden Oil Holdings Limited at an issuance price of CAD$0.075 per share.